A criticism by two Harvard University (Cambridge, Mass.) professors of the risk-reduction guidelines appears in The Lancet. The professors, cardiologist Paul Ridker, MD, and epidemiologist Nancy Cook, ScD, say the guidelines are reactionary and are too quick to put patients on statins, or cholesterol lowering drugs, they might not need.
While the guidelines have not yet been delayed, the guideline authors seem intent on addressing the concerns that have been raised to reaffirm the credibility of their work, according to the report.
According to the guideline authors, criticisms are based on three studies with sample populations demonstrating above-average health. The authors agree that while their risk assessment tool may be too heavy-duty for the populations in the studies Dr. Ridker and Dr. Cook analyzed, it is appropriate for the general population, one-third of which will die from stroke or heart-attack related complications, according to the report.
More Articles on Quality:
Meeting the Challenge of High Reliability
6 Factors Helping Prevent Misdiagnosis, Leading Cause of Malpractice Claims
Study: Cardiac Surgery-Related HAIs Show Incremental Cost
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.